+47.6%
ON vs MRNA
+945.0%
-897.5%
-50.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +13.1% | -15.0% | -1.9% |
| 7D | -5.8% | +20.6% | -26.4% | -5.8% |
| 30D | -17.1% | +27.1% | -44.2% | -17.0% |
| 3M | -11.8% | +353.4% | -365.2% | -11.3% |
| 6M | -30.2% | +446.3% | -476.4% | -33.5% |
| YTD | +31.6% | +776.2% | -744.6% | +10.7% |
| 1Y | +47.6% | +987.9% | -940.4% | +15.8% |
| All | +47.6% | +945.0% | -897.5% | +15.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling